Patrick M. Harrington

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications

Janus kinase inhibitors after ruxolitinib failure in myelofibrosis: A systematic review and pooled analysis of phase 3 efficacy and integrated safety across clinical trials and real-world evidence.

Janus kinase inhibitors after ruxolitinib failure in myelofibrosis: A systematic review and pooled analysis of phase 3 efficacy and integrated safety across clinical trials and real-world evidence.

Journal: British journal of haematology
Published: June 15, 2026

Blinatumomab for measurable residual disease relapse in acute myeloid leukemia with t(8;21) translocation: the BlinAML Trial.

Blinatumomab for measurable residual disease relapse in acute myeloid leukemia with t(8;21) translocation: the BlinAML Trial.

Journal: Haematologica
Published: April 21, 2026

A systematic review of 47 published cases of extramedullary hematopoiesis in myelofibrosis: clinical patterns, treatment responses, and prognostic implications.

A systematic review of 47 published cases of extramedullary hematopoiesis in myelofibrosis: clinical patterns, treatment responses, and prognostic implications.

Journal: Annals of hematology
Published: February 28, 2026

Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.

Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.

Journal: British journal of haematology
Published: February 25, 2026

Integrating Genomic and Clinical Data in AML: Real-World Application of the Sanger Multistage Model.

Integrating Genomic and Clinical Data in AML: Real-World Application of the Sanger Multistage Model.

Journal: Genes
Published: December 13, 2025

Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes.

Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes.

Journal: Leukemia
Published: November 06, 2025

Old Therapy, New Questions: Rethinking Phlebotomy in a Pharmacologic Landscape.

Old Therapy, New Questions: Rethinking Phlebotomy in a Pharmacologic Landscape.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: July 22, 2025

Rapid and durable recovery of immune effector cells in myelofibrosis patients treated with momelotinib.

Rapid and durable recovery of immune effector cells in myelofibrosis patients treated with momelotinib.

Journal: Haematologica
Published: June 20, 2025

Emerging Therapeutic Approaches for Anemia in Myelofibrosis.

Emerging Therapeutic Approaches for Anemia in Myelofibrosis.

Journal: Current hematologic malignancy reports
Published: March 31, 2025

QRISK3 score is predictive of thrombotic risk in patients with myeloproliferative neoplasms.

QRISK3 score is predictive of thrombotic risk in patients with myeloproliferative neoplasms.

Journal: Leukemia
Published: March 19, 2025

Development of a natural language processing pipeline for assessment of cardiovascular risk in myeloproliferative neoplasms.

Development of a natural language processing pipeline for assessment of cardiovascular risk in myeloproliferative neoplasms.

Journal: HemaSphere
Published: April 01, 2024

Polycythemia Vera: Barriers to and Strategies for Optimal Management.

Polycythemia Vera: Barriers to and Strategies for Optimal Management.

Journal: Blood and lymphatic cancer : targets and therapy
Published: September 27, 2023
Showing 1-12 of 36

Last Updated: 09/26/2026